Kane Biotech's gross profit for the
three
months ended in Mar. 2026 was $-0.00 Mil. Kane Biotech's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.04 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Kane Biotech's gross profit for the
three
months ended in Mar. 2026 was $-0.00 Mil. Kane Biotech's Revenue for the
three
months ended in Mar. 2026 was $0.03 Mil. Therefore, Kane Biotech's Gross Margin % for the quarter that ended in Mar. 2026 was -9.68%.
Kane Biotech had a gross margin of -9.68% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of Kane Biotech was 73.15%. The lowest was -81.03%. And the median was 37.64%.
Kane Biotech (OTCPK:KNBIF) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Kane Biotech had a gross margin of -9.68% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Kane Biotech Gross Profit Related Terms
Kane Biotech Gross Profit Historical Data
* Premium members only.
The historical data trend for Kane Biotech's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, ALNY: Gross Profit Comparison
For the Biotechnology subindustry, Kane Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's Gross Profit distribution charts can be found below:
* The bar in red indicates where Kane Biotech's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Kane Biotech (KNBIF) has a Gross Profit of $-0.04 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Kane Biotech and its competitors.
Is Kane Biotech's Gross Profit too high?
Kane Biotech's current Gross Profit is $-0.04 Mil.
How does Kane Biotech's Gross Profit compare to VRTX and REGN?
Kane Biotech's Gross Profit of $-0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Kane Biotech and its competitors. Kane Biotech's current Gross Profit is $-0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Gross Profit of $-0.04 Mil. The current Gross Profit is $-0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Gross Profit is $-0.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 